Worldquant Millennium Advisors LLC Increases Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Worldquant Millennium Advisors LLC increased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 26.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,981 shares of the company's stock after purchasing an additional 1,031 shares during the quarter. Worldquant Millennium Advisors LLC's holdings in Medpace were worth $1,655,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Lindbrook Capital LLC increased its stake in shares of Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after purchasing an additional 29 shares during the last quarter. HBK Sorce Advisory LLC raised its stake in Medpace by 0.5% during the 4th quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock valued at $1,789,000 after purchasing an additional 29 shares during the last quarter. Assetmark Inc. raised its stake in Medpace by 20.1% during the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after purchasing an additional 29 shares during the last quarter. Proficio Capital Partners LLC raised its stake in Medpace by 4.1% during the 4th quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock valued at $243,000 after purchasing an additional 29 shares during the last quarter. Finally, Schulhoff & Co. Inc. raised its stake in Medpace by 1.2% during the 4th quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company's stock valued at $874,000 after purchasing an additional 30 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Down 1.2%

Shares of MEDP traded down $3.55 during midday trading on Wednesday, reaching $295.04. 38,606 shares of the stock were exchanged, compared to its average volume of 352,600. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $459.77. The company has a market cap of $8.48 billion, a P/E ratio of 23.37, a PEG ratio of 3.81 and a beta of 1.55. The stock's 50 day simple moving average is $300.76 and its 200 day simple moving average is $325.93.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $3.06 by $0.61. The firm had revenue of $558.57 million during the quarter, compared to the consensus estimate of $528.38 million. Medpace had a return on equity of 51.48% and a net margin of 19.17%. During the same quarter in the previous year, the firm earned $3.20 earnings per share. As a group, analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insider Activity at Medpace

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the firm's stock in a transaction dated Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the sale, the director now owns 2,998 shares of the company's stock, valued at $904,856.36. This trade represents a 36.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 20.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on MEDP. William Blair restated a "market perform" rating on shares of Medpace in a research note on Tuesday, April 22nd. Leerink Partnrs raised shares of Medpace to a "hold" rating in a research note on Monday, March 24th. Leerink Partners began coverage on shares of Medpace in a research report on Monday, March 24th. They issued a "market perform" rating and a $330.00 price target on the stock. TD Cowen downgraded shares of Medpace from a "buy" rating to a "hold" rating and cut their price target for the company from $370.00 to $328.00 in a research report on Monday, April 14th. Finally, Mizuho dropped their target price on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a report on Wednesday, April 9th. Eleven research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $349.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.